文献速递淋巴瘤

血管内大B细胞淋巴瘤的临床特征:单中心回顾性研究

[Clinical characteristics of intravascular large B cell lymphoma: a single-center retrospective study].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2018-01-01

该单中心回顾性研究分析2010年1月至2016年6月诊断的12例血管内大B细胞淋巴瘤(IVLBCL)患者,发热最常见(10/12),肺受累6/12,噬血细胞综合征6/12。11例接受含利妥昔单抗的CHOP方案化疗,总反应率90.1%,完全缓解率66.7%。

要点

  • IVLBCL常见发热(10/12)、呼吸系统症状(6/12)和噬血细胞综合征(6/12)。
  • 11例接受CHOP或R-CHOP化疗者总反应率90.1%,完全缓解率66.7%。
  • 中位随访20个月,中位生存期及中位无进展生存期尚未达到。

核心结论

  • IVLBCL临床罕见,出现肺部受累比例高,肺活检有较高阳性率。
  • R-CHOP方案目前仍是最主要的治疗方案。

研究设计与样本

  • 回顾性分析北京协和医院2010年1月至2016年6月收治的12例IVLBCL患者的临床资料。
  • 采用Kaplan-Meier法估计总生存期,单因素分析识别预后因素。

主要发现

  • 12例患者中男6例、女6例,中位年龄58.5岁(范围32~76岁)。
  • 发热最常见(10/12),呼吸系统症状(咳嗽、呼吸困难、胸腔积液等)6/12,噬血细胞综合征6/12,神经系统症状1/12。
  • 所有患者均有乳酸脱氢酶升高(367~1700 U/L)、铁蛋白升高(805~1527 μg/L)及结外器官受累,肺6例、骨髓3例、脑2例,软脑膜、肾上腺、副鼻窦、胆囊、甲状腺各1例。
  • 国际预后指数评分高的患者占75%。
  • 11例接受CHOP或R-CHOP方案化疗,总反应率90.1%,完全缓解率66.7%。

关键数值与推荐

  • 光镜下可见分布于小血管内的单个或小簇状淋巴瘤细胞,毛细血管或血窦结构得以保留。
  • 免疫组化显示CD20、CD79a等B淋巴细胞标志阳性。

临床怎么用

  • R-CHOP方案目前仍是最主要的治疗方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate clinic-pathological characteristics, diagnosis, treatment and prognosis of intravascular large B cell lymphoma (IVLBCL) in China. Methods: Clinical and pathological records were analyzed from 12 IVLBCL patients diagnosed between Jan 2010 to Jun 2016. Kaplan-Meier method was used to estimate overall survival (OS), and univariate analysis was performed to identify prognostic factors. Results: A series of 12 patients with IVLBCL (median age, 53.8 years; range, 32-76 years; 6 males and 6 females) was reviewed. Fever was the most common symptom (10/12), respiratory symptoms (cough, pleural effusion, dyspnea, 50%) and hemophagocytic lymphohistiocytosis (50%) were frequently observed, and only 12 patients had neurological symptom. All patients had elevated lactic dehydrogenase and serum ferritin. International Prognostic Index score was high in 75% of total patients. All patients had extra-nodal involved, pulmonary (6/12) and bone marrow (4/12) were frequently involved. Large lymphoid cells within vessel lumina or sinuses were observed in all patients. These cells were large, with scant cytoplasm, vesicular nuclei, and one or more nucleoli, and the structures of vessels and sinus were reserved. CD20 and CD79a were positive in all cases. 11patients received rituximab combined CHOP regimen chemotherapies, overall response rate (ORR) was 90.1%, and complete response rate was 66.7%. Median survival time and median progression time were not reached after a median follow-up of 20 months. Univariate analysis revealed that no clinical characters were associated with OS. Conclusion: As a rare variant of DLBCL, IVLBCL presented with pulmonary involved frequently, and trans-bronchial lung biopsy had good positive rates. Rituximab contained chemotherapy was the backbone for IVLBCL. 目的: 提高对血管内大B细胞淋巴瘤(IVLBCL)的认识。 方法: 回顾性分析北京协和医院自2010年1月至2016年6月收治的12例IVLBCL患者的临床资料。 结果: ①12例患者中,男6例,女6例,中位年龄为58.5(32~76)岁。临床表现:发热最为常见(10/12),其次为呼吸系统症状(咳嗽、呼吸困难、胸腔积液等,6/12)、噬血细胞综合征(6/12)、神经系统症状(1/12);所有患者均有LDH升高(367~1 700 U/L)、铁蛋白升高(805~1 527 μg/L)、结外器官受累(肺6例,骨髓3例,脑2例,软脑膜、肾上腺、副鼻窦、胆囊、甲状腺各1例)。②组织病理特征:光镜下可见分布于小血管内的单个或小簇状淋巴瘤细胞,毛细血管或血窦结构得以保留,免疫组化显示CD20、CD79a等B淋巴细胞标志阳性。③疗效及预后:11例患者接受CHOP或R-CHOP方案化疗,其总反应率为90.1%,完全缓解率为66.7%。患者平均随访20(1~40)个月,中位生存期及中位无进展生存期尚未达到。单因素Cox回归分析未能发现年龄、分期、IPI等临床参数与预后相关。 结论: IVLBCL临床罕见,出现肺部受累比例高,肺活检有较高阳性率;R-CHOP方案目前仍是最主要的治疗方案。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Zhu TN, Sun J, et al. [Clinical characteristics of intravascular large B cell lymphoma: a single-center retrospective study]. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 30612402. doi:10.3760/cma.j.issn.0253-2727.2018.12.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。